Literature DB >> 32064646

Measuring the impact of risk communications: Robust analytical approaches are key.

Peter Arlett1.   

Abstract

Keywords:  impact research; pharmacovigilance; risk communication; risk management

Mesh：

Year:  2020        PMID： 32064646      PMCID： PMC7098862          DOI： 10.1111/bcp.14222

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  6 in total

1.  Proactively managing the risk of marketed drugs: experience with the EMA Pharmacovigilance Risk Assessment Committee.

Authors:  Peter Arlett; Geraldine Portier; Roberto de Lisa; Kevin Blake; Noel Wathion; Jean-Michel Dogne; Almath Spooner; June Raine; Guido Rasi
Journal:  Nat Rev Drug Discov       Date:  2014-04-22       Impact factor: 84.694

2.  Measuring the impact of risk communications: Robust analytical approaches are key.

Authors:  Peter Arlett
Journal:  Br J Clin Pharmacol       Date:  2020-02-16       Impact factor: 4.335

3.  Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works.

Authors:  Aniello Santoro; Georgy Genov; Almath Spooner; June Raine; Peter Arlett
Journal:  Drug Saf       Date:  2017-10       Impact factor: 5.606

4.  Correction: Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation.

Authors: 
Journal:  BMJ Open       Date:  2019-02-22       Impact factor: 2.692

5.  Good Signal Detection Practices: Evidence from IMI PROTECT.

Authors:  Antoni F Z Wisniewski; Andrew Bate; Cedric Bousquet; Andreas Brueckner; Gianmario Candore; Kristina Juhlin; Miguel A Macia-Martinez; Katrin Manlik; Naashika Quarcoo; Suzie Seabroke; Jim Slattery; Harry Southworth; Bharat Thakrar; Phil Tregunno; Lionel Van Holle; Michael Kayser; G Niklas Norén
Journal:  Drug Saf       Date:  2016-06       Impact factor: 5.606

6.  The RIMES Statement: A Checklist to Assess the Quality of Studies Evaluating Risk Minimization Programs for Medicinal Products.

Authors:  Meredith Y Smith; Andrea Russell; Priya Bahri; Peter G M Mol; Sarah Frise; Emily Freeman; Elaine H Morrato
Journal:  Drug Saf       Date:  2018-04       Impact factor: 5.606
  6 in total
  2 in total

1.  Measuring the impact of risk communications: Robust analytical approaches are key.

Authors:  Peter Arlett
Journal:  Br J Clin Pharmacol       Date:  2020-02-16       Impact factor: 4.335

2.  Impact of regulatory interventions to restrict the combined use of renin-angiotensin system blockers: A Danish nationwide drug utilisation study.

Authors:  Per Sindahl; Richard Ofori-Asenso; Christine Erikstrup Hallgreen; Kaare Kemp; Helga Gardarsdottir; Marie Louise De Bruin
Journal:  Br J Clin Pharmacol       Date:  2021-10-08       Impact factor: 3.716
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.